Hyderabad: DFE Pharma inaugurates new CoE at Genome Valley

Written by Ruchika Sharma Published On 2022-09-13T15:00:25+05:30 | Updated On 13 Sep 2022 9:30 AM GMT

Hyderabad: DFE Pharma inaugurates new CoE at Genome Valley

The services offered by this new center, mainly focus on oral solid dosage (OSD) forms and comprise a range of pre-registration work including development, scale-up, and technology transfer.

Hyderabad: DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, on Monday announced it has celebrated the opening ceremony of its new "Closer to the Formulator" (C2F), a Center of Excellence (CoE), at Genome Valley, the largest pharma and life sciences hub in Asia in HyderabadC2F helps pharmaceutical companies to shorten the time from concept to finished...

Hyderabad: DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, on Monday announced it has celebrated the opening ceremony of its new "Closer to the Formulator" (C2F), a Center of Excellence (CoE), at Genome Valley, the largest pharma and life sciences hub in Asia in Hyderabad

C2F helps pharmaceutical companies to shorten the time from concept to finished commercial product through its expertise in all phases of pharmaceutical development.

Telangana Minister for Industries, K.T. Rama Rao (known as KTR) inaugurated the centre in the presence of Principal Secretary (IT and Industries) Jayesh Ranjan, Director (Life Sciences and Pharma) Shakthi Nagappan, DFE Pharma CEO,Martti Hedman and C2F CoE Director Dr. Anilkumar Gandhi.

With the C2F center, Germany-based DFE Pharma aims to support global and local pharmaceutical and nutraceutical companies to address these challenges, by developing robust formulations allowing for scale-up, high-speed production, and first-to-market launch.

The cutting-edge 1200 sq meters laboratory facilities of the C2F center are equipped with the latest technology and staffed by highly experienced scientists.

The services offered by this new center, mainly focus on oral solid dosage (OSD) forms and comprise a range of pre-registration work including development, scale-up, and technology transfer.

The center works with active pharmaceutical ingredients (APIs)*, including innovative concepts as model APIs; and with a broad portfolio of all categories of excipients and their different grades.

Speaking on the occasion, KTR said, " I firmly believe that C2F will further strengthen the potential for growth and support offered by Genome Valley. The Government of Telangana will work with DFE Pharma to ensure that Life Sciences companies in the state leverage from this facility."

Speaking about C2F, Martti Hedman, said: "With our C2F center, based at a prime location in the pharma and life sciences hub Genome Valley, we can help pharmaceutical and nutraceutical companies progress their projects faster and further. Through our capabilities, we not only support our customers to develop high-quality products but also improve their efficiencies".

"We aim to closely work with our customers to help them develop new ideas, together we address their challenges using our expertise in the latest pharmaceutical trends" explained Dr. Anilkumar Gandhi.

"The capabilities offered through this center can reduce the time to launch a product, without compromising quality, while reducing the number of development assays and therefore decreasing formulation spending," Dr Gandhi added.

Source : UNI

Ruchika Sharma

M.Com

Ruchika joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751